ArticleResearch square2025
Systematic characterization of cell type-specific master metabolic regulators in Alzheimer's disease.
Yunguang Qiu, Yuan Hou, Liam Wetzel, Jessica Z K Caldwell, Xiongwei Zhu, Andrew A Pieper, Tian Liu, Feixiong Cheng
Abstract readPreprint
In one paragraphArticle in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Yuan HouCleveland Clinic Genome Center, Cleveland Clinic Research, Cleveland Clinic, Cleveland, OH 44195, USA.
Liam WetzelDepartment of Pathology, Case Western Reserve University, School of Medicine, Cleveland, OH 44106, USA.
Jessica Z K CaldwellLou Ruvo Center for Brain Health, Neurological Institute, Cleveland Clinic, Las Vegas, NV 89106, USA.
Andrew A PieperDepartment of Pathology, Case Western Reserve University, School of Medicine, Cleveland, OH 44106, USA.
Tian LiuDepartment of Pathology, Case Western Reserve University, School of Medicine, Cleveland, OH 44106, USA.
Funding
Translational and Therapeutics CoreP30AG072959 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI JAGAN AYYAPPAN PILLAI · 2021 to 2026
$23.9MEndophenotype Network-based Approaches to Prediction and Population-based Validation of In Silico Drug Repurposing for Alzheimer's DiseaseR01AG066707 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI Feixiong Cheng · 2020 to 2026
$4.9MTREM2 Genotype-Informed Drug Repurposing and Combination Therapy Design for Alzheimers DiseaseR01AG076448 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI Feixiong Cheng, Li Gan · 2022 to 2026
$4.0MAlzheimer's MultiOme Data Repurposing: Artificial Intelligence, Network Medicine, and Therapeutics DiscoveryU01AG073323 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI BEKRIS, LYNN, CHENG, FEIXIONG · 2021 to 2025
$4.0MAlzheimer's Disease and Related Dementia-like Sequelae of SARS-CoV-2 Infection: Virus-Host Interactome, Neuropathobiology, and Drug RepurposingRF1AG082211 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI CHENG, FEIXIONG, PIEPER, ANDREW A · 2023 to 2023
$2.4MCharacterize neuronal and glial cell-specific vulnerability to proteinopathies in Alzheimer's disease using multimodal single-nuclei genomic and epigenomic approachesR01AG082118 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI BONAKDARPOUR, BORNA, CHENG, FEIXIONG · 2023 to 2025
$2.4MDark GPCR signaling underlying the Microbiome-Gut-Brain Axis for Alzheimer's Disease and Related DementiaRF1NS133812 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · PI BROWN, JONATHAN MARK, CHENG, FEIXIONG · 2023 to 2023
$2.3MMicroglial Activation and Inflammatory Endophenotypes Underlying Sex Differences of Alzheimer’s DiseaseR01AG084250 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI Feixiong Cheng, Justin D. Lathia · 2023 to 2026
$2.2MProtective Role of Mitochondrial CHCHD10 in Alzheimer's Disease through MAM and Mitophagy Mechanisms.R01AG086365 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI Tian Liu · 2024 to 2026
$1.9MA Multimodal, Multiscale and Multistage Systems Biology (M3SB) Infrastructure for Precision Medicine in Alzheimer’s Disease and LongevityR01AG092591 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI Feixiong Cheng, ANDREW J SAYKIN · 2025 to 2026
$1.6MMapping proteomic changes of tauopathy in human neuronsR01AG092462 · NIA · WEILL MEDICAL COLL OF CORNELL UNIV · PI Feixiong Cheng, Li Gan · 2025 to 2026
$1.4MPrecision Medicine Digital Twins for Alzheimer’s Target and Drug Discovery and LongevityR21AG083003 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI CHENG, FEIXIONG · 2023 to 2023
$483kBLRD VA I01 BX005976NIA NIH HHS P30 AG072959NIA NIH HHS R01 AG066707NIA NIH HHS R01 AG076448NIA NIH HHS R01 AG082118NIA NIH HHS R01 AG084250NIA NIH HHS R01 AG086365NIA NIH HHS R01 AG092462NIA NIH HHS R01 AG092591NIA NIH HHS R03 AG084948NIA NIH HHS R21 AG083003NIA NIH HHS RF1 AG082211NIA NIH HHS U01 AG073323NINDS NIH HHS RF1 NS133812
6 · The paper itselfAbstract
Alzheimer's disease (AD) exhibits metabolic heterogeneity; yet, the consequences on metabolic dynamics in a cell-type-specific manner and the underlying metabolite-sensor network basis remain unclear. Here, we show that neurons exhibit a striking decrease in energy and lipid-related metabolic activity, contrasted by an increase in microglial metabolism associated with neuroinflammation. To identify brain cell-type specific master metabolic regulators underlying the metabolic alterations of AD, we introduce scFUMES (
Identifiers
PMID40894034
PMCPMC12393479
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390